Abstract Introduction: The phase III IMbrave150 study established atezolizumab+
bevacizumab as standard of care in patients with unresectable hepatocellular carcinoma …

Background Adjuvant therapy may improve survival of patients with hepatocellular
carcinoma (HCC) after curative resection. This study compared safety and efficacy outcomes …

Introduction: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma
(HCC). We aimed to compare the clinical outcomes of lenvatinib plus drug-eluting beads …

Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone
remarkable development. Various systemic chemotherapy drugs have been approved and …

Hepatocellular carcinoma (HCC) is refractory to treatment under the following conditions:(A)
a large number of tumors,(B) large tumor size,(C) vascular invasion or extrahepatic spread …

Background: The aim of the present study is to determine the feasibility of biopsy for atypical
liver nodules in patients under surveillance for hepatocellular carcinoma (HCC), assessing …

Stereotactic body radiotherapy (SBRT), a type of external beam radiotherapy, yields local
control of hepatocellular carcinoma (HCC) at rates as high as 90%. SBRT has been …

Introduction: Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and lenvatinib
exhibits strong antitumor effects against advanced hepatocellular carcinoma (HCC). Higher …

Aim The present study focused on Geriatric Nutritional Risk Index (GNRI), which is based on
bodyweight and serum albumin, and known as an easy‐to‐use nutritional assessment tool …

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with high
mortality. The realization of precision medicine in HCC relies upon efficient biomarkers …